Boston Scientific to Market Angioplasty Device

Following a series of agreements, exclusive global distribution rights to a new angioplasty device have been acquired by Boston Scientific Corp. (Natick, MA, USA) from CryoVascular Systems, Inc. (Los Gatos, CA, USA).

The device, designed to treat atherosclerotic disease of the legs and peripheral arteries, has been cleared by the US Food and Drug Administration (FDA) and has received the CE Mark. The device is based on new technology developed by CryoVascular called PolarCath, which utilizes liquid nitrous oxide to provide precise freezing of diseased arteries during balloon angioplasty. The procedure is designed to reduce the rate of restenosis, which often requires patients to have angioplasty again. Current balloon angioplasty and stent technology have a high rate of repeat procedures, reported to be as high as 45%.

A post-market clinical study of the new device is now under way. Boston Scientific's agreement with CryoVascular also includes the right to make an equity investment in the company and an option to acquire the company in the future.

"We are excited about the early trial results of the CryoPlasty procedure, which suggest improved outcomes in challenging cases,” said Paul LaViolette, senior vice president and group president, cardiovascular, at Boston Scientific. "Boston Scientific is continually searching for innovative ways to treat patients suffering from peripheral vascular disease.”



Related Links:
Boston Scientific
CryoVascular